Neurolief Ltd. received FDA clearance for its Relivion system for home treatment of acute migraine. The noninvasive multichannel brain neuromodulation system, worn as a headset, stimulates the occipital and trigeminal nerves.

Corvista Health Inc. has raised $65 million in a series C equity financing led by Ambix Life Science Fund I LP. The new funds are earmarked for ongoing research, product development and commercialization of the company’s noninvasive, point-of-care (POC) solution for rapid detection of heart disease. Joining Ambix in the round were Medventure Partners and several new and existing investors. With this latest infusion, Corvista has raised a total of nearly $100 million.

A bad patient experience with telehealth can blunt adoption regardless of the incentives for developers and doctors. Griffin Mulcahey, chief compliance officer at Wheel Health Inc., of Austin, Texas, said during a recent webinar that users of these digital health apps and telemedicine programs may need assistance to get up to speed on an application, a critical effort that may make the difference between success and failure in telehealth.

HONG KONG – Researchers at Ben-Gurion University of the Negev (BGU) in Israel have developed a way to instantly monitor blood levels of the antipsychotic drug clozapine. BGU’s solution is based on an electrochemical microsensor developed by Hadar Ben-Yoav from BGU’s Department of Biomedical Engineering and Ilse Katz Institute for Nanoscale Science and Technology.